Free Trial
NASDAQ:CRMD

CorMedix (CRMD) Stock Price, News & Analysis

CorMedix logo
$11.32 -0.03 (-0.24%)
As of 09:45 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About CorMedix Stock (NASDAQ:CRMD)

Key Stats

Today's Range
$11.39
$11.39
50-Day Range
$9.03
$16.56
52-Week Range
$3.61
$17.43
Volume
1,092 shs
Average Volume
1.35 million shs
Market Capitalization
$767.93 million
P/E Ratio
51.25
Dividend Yield
N/A
Price Target
$17.14
Consensus Rating
Moderate Buy

Company Overview

CorMedix Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
57th Percentile Overall Score

CRMD MarketRank™: 

CorMedix scored higher than 57% of companies evaluated by MarketBeat, and ranked 460th out of 920 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    CorMedix has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 5 buy ratings, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    CorMedix has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about CorMedix's stock forecast and price target.
  • Earnings Growth

    Earnings for CorMedix are expected to grow in the coming year, from ($0.32) to $0.94 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of CorMedix is 51.59, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.82.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of CorMedix is 51.59, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 27.99.

  • Price to Book Value per Share Ratio

    CorMedix has a P/B Ratio of 8.11. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about CorMedix's valuation and earnings.
  • Percentage of Shares Shorted

    13.37% of the float of CorMedix has been sold short.
  • Short Interest Ratio / Days to Cover

    CorMedix has a short interest ratio ("days to cover") of 4.
  • Change versus previous month

    Short interest in CorMedix has recently increased by 0.70%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    CorMedix does not currently pay a dividend.

  • Dividend Growth

    CorMedix does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    13.37% of the float of CorMedix has been sold short.
  • Short Interest Ratio / Days to Cover

    CorMedix has a short interest ratio ("days to cover") of 4.
  • Change versus previous month

    Short interest in CorMedix has recently increased by 0.70%, indicating that investor sentiment is decreasing.
  • News Sentiment

    CorMedix has a news sentiment score of 0.99. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for CorMedix this week, compared to 5 articles on an average week.
  • Search Interest

    4 people have searched for CRMD on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.
  • MarketBeat Follows

    7 people have added CorMedix to their MarketBeat watchlist in the last 30 days. This is an increase of 75% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, CorMedix insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 5.30% of the stock of CorMedix is held by insiders.

  • Percentage Held by Institutions

    Only 34.18% of the stock of CorMedix is held by institutions.

  • Read more about CorMedix's insider trading history.
Receive CRMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CorMedix and its competitors with MarketBeat's FREE daily newsletter.

CRMD Stock News Headlines

Brokers Set Expectations for CorMedix FY2027 Earnings
D Boral Capital Downgrades CorMedix (NASDAQ:CRMD) to Hold
How a Kansas farm boy gained 1,285% in two days
A former farm kid placed a simple trade… and cashed out a 1,285% gain two days later. It wasn’t crypto or a meme stock. It was a pattern called “Crossfire” — a 3-step setup you can execute in a normal brokerage app. Master trader Jeff Clark is now revealing how it works in a free 30-minute video, available for a limited time.
Equities Analysts Offer Predictions for CorMedix Q2 Earnings
CorMedix Seems Significantly Undervalued
See More Headlines

CRMD Stock Analysis - Frequently Asked Questions

CorMedix's stock was trading at $8.10 at the start of the year. Since then, CRMD stock has increased by 40.1% and is now trading at $11.35.

CorMedix Inc (NASDAQ:CRMD) announced its quarterly earnings results on Tuesday, May, 6th. The company reported $0.30 EPS for the quarter, beating the consensus estimate of $0.25 by $0.05. The company earned $39.08 million during the quarter, compared to analysts' expectations of $38.90 million. CorMedix had a net margin of 20.81% and a trailing twelve-month return on equity of 22.57%.
Read the conference call transcript
.

CorMedix shares reverse split on Tuesday, March 26th 2019.The 1-5 reverse split was announced on Thursday, March 21st 2019. The number of shares owned by shareholders was adjusted after the market closes on Monday, March 25th 2019. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.

Top institutional investors of CorMedix include GSG Advisors LLC (0.02%). Insiders that own company stock include Joseph Todisco, Erin Mistry and Elizabeth Hurlburt.
View institutional ownership trends
.

Shares of CRMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that CorMedix investors own include Voyager Therapeutics (VYGR), Waste Connections (WCN), American Water Works (AWK), DiamondRock Hospitality (DRH), AU Optronics (AUOTY), Marinus Pharmaceuticals (MRNS) and The RMR Group (RMR).

Company Calendar

Last Earnings
5/06/2025
Today
7/10/2025
Next Earnings (Estimated)
8/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CRMD
CIK
1410098
Employees
30
Year Founded
N/A

Price Target and Rating

High Price Target
$20.00
Low Price Target
$13.00
Potential Upside/Downside
+51.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.88
Research Coverage
8 Analysts

Profitability

Trailing P/E Ratio
51.59
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$17.93 million
Pretax Margin
20.81%

Debt

Sales & Book Value

Annual Sales
$43.47 million
Price / Cash Flow
N/A
Book Value
$1.40 per share
Price / Book
8.11

Miscellaneous

Free Float
64,230,000
Market Cap
$769.76 million
Optionable
Optionable
Beta
1.58
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

This page (NASDAQ:CRMD) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners